Vanguard Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History
Bought
Maintained
Sold
Other funds holding PHAT
6CM
Vanguard Capital Management's PHAT Position: Q3 2026 in Review
Vanguard Capital Management increased its Phathom Pharmaceuticals (PHAT) stake by 2.9% in Q3 2026, buying an estimated $737K and bringing the position to 2,735,113 shares worth $20M. The position accounts for ﹤0.01% of the portfolio, ranked #2403.
Vanguard Capital Management first reported a position in PHAT in Q1 2026 and has held it in 3 quarters since. The position peaked at $28.8M in Q2 2026. 161 funds tracked by Wall St. Rank hold PHAT as of Q3 2026.
- Vanguard Capital Management held 2,735,113 shares of Phathom Pharmaceuticals worth $20M as of Q3 2026.
- Vanguard Capital Management bought 78,169 Phathom Pharmaceuticals shares in Q3 2026, an estimated $737K.
- Phathom Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2403 holding.
- Vanguard Capital Management first reported a position in Phathom Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Phathom Pharmaceuticals position peaked at $28.8M in Q2 2026.
- 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.